Using genetic approaches to remove PSGL-1 inhibition through the use of cellular therapies such as re-injection of expanded tumor-infiltrating lymphocytes, CAR-T cells, or dendritic cell-based cancer vaccines could be another approach to modulate the tumor microenvironment (Figure 4). Here, SELPLG is linked to neoplasm.